X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9930) 9930
Newsletter (129) 129
Book / eBook (18) 18
Book Chapter (16) 16
Magazine Article (12) 12
Newspaper Article (4) 4
Web Resource (3) 3
Reference (2) 2
Report (2) 2
Transcript (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9099) 9099
science & technology (7867) 7867
life sciences & biomedicine (7747) 7747
female (5313) 5313
oncology (4511) 4511
male (4363) 4363
middle aged (3576) 3576
adult (3313) 3313
aged (2861) 2861
chemotherapy (2760) 2760
cancer (2671) 2671
antineoplastic combined chemotherapy protocols - therapeutic use (2420) 2420
antineoplastic agents - adverse effects (2081) 2081
treatment outcome (2068) 2068
antineoplastic agents, alkylating - adverse effects (2000) 2000
antineoplastic agents - therapeutic use (1924) 1924
hematology (1829) 1829
antineoplastic combined chemotherapy protocols - adverse effects (1763) 1763
animals (1552) 1552
care and treatment (1541) 1541
antineoplastic agents, alkylating - therapeutic use (1423) 1423
medicine & public health (1314) 1314
antineoplastic agents, alkylating - administration & dosage (1291) 1291
antineoplastic agents (1214) 1214
pharmacology & pharmacy (1170) 1170
adolescent (1155) 1155
neoplasms - drug therapy (1074) 1074
antimitotic agents (1065) 1065
research (1042) 1042
combined modality therapy (998) 998
child (975) 975
aged, 80 and over (948) 948
health aspects (915) 915
disease-free survival (897) 897
retrospective studies (897) 897
risk factors (872) 872
dacarbazine - analogs & derivatives (857) 857
antineoplastic agents - administration & dosage (856) 856
prognosis (852) 852
cyclophosphamide - administration & dosage (823) 823
drug therapy (794) 794
abridged index medicus (750) 750
antineoplastic combined chemotherapy protocols - administration & dosage (738) 738
cyclophosphamide - adverse effects (737) 737
analysis (712) 712
drug administration schedule (712) 712
brain neoplasms - drug therapy (694) 694
follow-up studies (693) 693
breast neoplasms - drug therapy (684) 684
dose-response relationship, drug (676) 676
cyclophosphamide (668) 668
survival rate (659) 659
temozolomide (654) 654
survival analysis (643) 643
child, preschool (642) 642
hematology, oncology and palliative medicine (642) 642
antineoplastic agents - pharmacology (624) 624
young adult (611) 611
multiple myeloma - drug therapy (592) 592
radiotherapy (580) 580
neoplasm staging (578) 578
breast cancer (553) 553
dacarbazine - therapeutic use (553) 553
dacarbazine - adverse effects (549) 549
multiple myeloma (549) 549
transplantation (546) 546
tumors (529) 529
clinical trials as topic (520) 520
clinical trials (507) 507
time factors (504) 504
mice (502) 502
toxicity (474) 474
neurosciences & neurology (464) 464
dosage and administration (457) 457
cancer therapies (447) 447
clinical neurology (431) 431
internal medicine (424) 424
infant (420) 420
patients (418) 418
radiotherapy - adverse effects (418) 418
recurrence (416) 416
pediatrics (413) 413
pharmacology/toxicology (404) 404
dacarbazine - administration & dosage (403) 403
leukemia (393) 393
disease progression (391) 391
prospective studies (390) 390
stem cells (389) 389
doxorubicin - administration & dosage (386) 386
glioblastoma - drug therapy (384) 384
remission induction (382) 382
surgery (381) 381
leukemia, lymphocytic, chronic, b-cell - drug therapy (372) 372
lymphomas (371) 371
melphalan - administration & dosage (371) 371
drug resistance, neoplasm (364) 364
hematopoietic stem cell transplantation (357) 357
complications and side effects (351) 351
cyclophosphamide - therapeutic use (348) 348
drug therapy, combination (346) 346
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9867) 9867
French (87) 87
Japanese (61) 61
German (56) 56
Russian (40) 40
Spanish (20) 20
Chinese (16) 16
Polish (16) 16
Italian (8) 8
Norwegian (8) 8
Dutch (7) 7
Hungarian (6) 6
Portuguese (6) 6
Czech (5) 5
Danish (3) 3
Finnish (3) 3
Hebrew (2) 2
Swedish (2) 2
Ukrainian (2) 2
Arabic (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer chemotherapy and pharmacology, ISSN 0344-5704, 8/2011, Volume 68, Issue 2, pp. 445 - 455
The natural flavonoid fisetin was recently identified as a lead compound that stabilizes endothelial cell microtubules. In this study, we investigated the... 
Fisetin | Lewis lung carcinoma | Angiogenesis | Antitumour activity | Cyclophosphamide | Medicine & Public Health | Cancer Research | Oncology | Cytotoxicity | EA·hy 926 endothelial cells | Pharmacology/Toxicology | Flavonoid | EA•hy 926 endothelial cells | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | NIH 3T3 Cells | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Tubulin Modulators - pharmacology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Alkylating - pharmacology | Flavonoids - adverse effects | Antineoplastic Agents, Alkylating - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Flavonoids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Angiogenesis Inhibitors - administration & dosage | Antineoplastic Agents, Phytogenic - administration & dosage | Angiogenesis Inhibitors - therapeutic use | Flavonoids - administration & dosage | Tubulin Modulators - administration & dosage | Female | Flavonoids - pharmacology | Antineoplastic Agents, Phytogenic - therapeutic use | Angiogenesis Inhibitors - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Cell Line | Cell Survival - drug effects | Tubulin Modulators - adverse effects | Mice, Inbred C57BL | Angiogenesis Inhibitors - pharmacology | Tubulin Modulators - therapeutic use | Carcinoma, Lewis Lung - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Cell Movement - drug effects | Animals | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Endothelial Cells - cytology | Neovascularization, Pathologic - drug therapy | Cyclophosphamide - pharmacology | Carcinoma, Lewis Lung - pathology | Cell Proliferation - drug effects | Mice | Antineoplastic Agents, Alkylating - adverse effects | Antineoplastic Agents, Phytogenic - pharmacology | Cell Cycle - drug effects | Endothelial Cells - drug effects | Antimitotic agents | Flavonoids | Flavones | Lung cancer | Bioflavonoids | Accountants | Drug therapy, Combination | Universities and colleges | Antineoplastic agents | Endothelium | Tumors | Index Medicus | cytology | Antineoplastic Agents, Phytogenic | pathology | Cell Proliferation | Endothelial Cells | Tubulin Modulators | Neovascularization, Pathologic | fisetin | administration & dosage | pharmacology | flavonoid | Carcinoma, Lewis Lung | Antineoplastic Agents, Alkylating | cytotoxicity | drug therapy | Cell Survival | angiogenesis | Antineoplastic Combined Chemotherapy Protocols | drug effects | Tumor Burden | Angiogenesis Inhibitors | EA.hy 926 | Cell Cycle | antitumour activity | adverse effects | therapeutic use | Cell Movement
Journal Article
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1215 - 1223
Journal Article
The Lancet (British edition), ISSN 0140-6736, 04/2016, Volume 387, Issue 10028, pp. 1629 - 1637
Journal Article
The Lancet (British edition), ISSN 0140-6736, 05/2015, Volume 385, Issue 9980, pp. 1873 - 1883
... patients and toxic effects are more pronounced than with chlorambucil. Therefore, chlorambucil is the standard of care for many patients with chronic lymphocytic... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Age Distribution | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Chlorambucil - adverse effects | Prospective Studies | Chlorambucil - therapeutic use | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents, Alkylating - administration & dosage | Aged, 80 and over | Adult | Female | Chlorambucil - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Treatment Outcome | Antineoplastic Agents, Alkylating - therapeutic use | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sex Distribution | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Antineoplastic Agents, Alkylating - adverse effects | Chlorambucil | Medical colleges | Hospitals | Comorbidity | United Kingdom | Product development | India | Medical research | Flow cytometry | Immunoglobulins | Medical imaging | Laboratories | Cytotoxicity | Infections | Ovarian cancer | Bone marrow | Drug dosages | Age | Binding sites | Geriatrics | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Pancreas, ISSN 0885-3177, 2017, Volume 46, Issue 6, pp. 758 - 763
Journal Article
The New England journal of medicine, ISSN 1533-4406, 09/2014, Volume 371, Issue 10, pp. 895 - 905
.... However, since autologous stem-cell transplantation has substantial toxic effects and requires prolonged hospitalization, the comparison with less toxic, orally administered treatments is important... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Transplantation, Autologous | Consolidation Chemotherapy | Antineoplastic Agents, Alkylating - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Melphalan - adverse effects | Adult | Maintenance Chemotherapy | Neutropenia - chemically induced | Thalidomide - adverse effects | Prednisone - administration & dosage | Prednisone - adverse effects | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Aged | Antineoplastic Agents, Alkylating - adverse effects | Stem Cell Transplantation - adverse effects | Complications and side effects | Care and treatment | Patient outcomes | Multiple myeloma | Stem cells | Transplantation | Research | Health aspects | Autografts | Chemotherapy | Cell survival | Transplants & implants | Melphalan | Stem cell transplantation | Death | Prednisone | Drug dosages | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article